Forte Biosciences, Inc. financial data

Symbol
FBRX on Nasdaq
Industry
Pharmaceutical Preparations
Location
3060 Pegasus Park Drive, Building 6, Dallas, TX
State of incorporation
DE
Fiscal year end
December 31
Former names
Tocagen Inc (to 6/15/2020)
Latest financial report
10-Q - Q3 2024 - Nov 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 458 % -39%
Return On Equity -151 % -70.2%
Return On Assets -119 % -53.9%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 1.46M shares -96%
Common Stock, Shares, Outstanding 1.46M shares -96%
Entity Public Float 20.4M USD +16.6%
Common Stock, Value, Issued 1K USD -97.2%
Weighted Average Number of Shares Outstanding, Basic 21M shares +42.6%
Weighted Average Number of Shares Outstanding, Diluted 21M shares +42.6%

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense 16.1M USD +56.9%
Operating Income (Loss) -35.6M USD -14.8%
Net Income (Loss) Attributable to Parent -34.2M USD -12.2%
Earnings Per Share, Basic 1.34 USD/shares +30.9%
Earnings Per Share, Diluted 1.34 USD/shares +30.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 16.4M USD -64.6%
Assets, Current 17.7M USD -62.5%
Property, Plant and Equipment, Net 86K USD -12.2%
Other Assets, Noncurrent 192K USD -71.7%
Assets 17.9M USD -62.5%
Accounts Payable, Current 5.16M USD -3.64%
Accrued Liabilities, Current 3.42M USD +61.6%
Liabilities, Current 8.58M USD +14.8%
Accumulated Other Comprehensive Income (Loss), Net of Tax 1K USD
Retained Earnings (Accumulated Deficit) -147M USD -30.4%
Stockholders' Equity Attributable to Parent 9.37M USD -76.8%
Liabilities and Equity 17.9M USD -62.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -6.67M USD -28.1%
Net Cash Provided by (Used in) Financing Activities -8K USD -233%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 1.46M shares -96%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -6.68M USD -28.5%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 16.4M USD -64.6%
Deferred Tax Assets, Valuation Allowance 18.6M USD +52.3%
Deferred Tax Assets, Gross 18.6M USD +52.3%
Depreciation 9K USD
Payments to Acquire Property, Plant, and Equipment 6K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -34.2M USD +15.8%
Property, Plant and Equipment, Gross 124K USD
Deferred Tax Assets, Operating Loss Carryforwards 6.52M USD +7.88%
Share-based Payment Arrangement, Expense 3.18M USD -5.53%